Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Intellia

Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here?

Cathie Wood recently acquired shares of the biotech company. Should you do the same?

Barchart

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

MarketBeat

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Analysts Think These Stocks Could More Than Double in Value

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

MarketBeat

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

Barchart

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

MarketBeat

2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025

Both penny stocks are a 'strong buy' on Wall Street.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Benzinga

This Cathie Wood Stock Can Soar 221%, Says Wall Street

Promising clinical trial results have analysts optimistic about the company’s future.

Barchart

Should You Buy These Breakout Cathie Wood Stocks Now?

All three are emerging players in their respective industries, with huge long-term potential.

Barchart

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Barchart

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

Investors Business Daily

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing

The FDA gave Intellia the go-ahead to begin a pivotal study of its gene-editing treatment for a heart disease, but NTLA stock fell.

Investors Business Daily

CRISPR Stock Intellia Therapeutics Thinks It Has The Cure To A Swelling Disorder

NTLA stock rose Monday after Intellia said its CRISPR-based gene-editing drug almost totally eliminated attacks in a swelling disease.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Inverse

Alzheimer’s-Like Diseases Can Affect the Body — Scientists Are Working to Find Out Why

Amyloid plaque can build up in body organs other than the brain, and today's treatments have a ways to go.

Investors Business Daily

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing

The FDA cleared Intellia to begin testing its CRISPR gene-editing technology in people on Thursday, leading NTLA stock to jump.

Investors Business Daily

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.

Investors Business Daily

Intellia, Other CRISPR Stocks Hammered On Safety Concerns In New Gene-Editing Test

Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

Investors Business Daily

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.

Investors Business Daily

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.

Benzinga

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis. Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data,…

Benzinga

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

StockNews.com

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

Benzinga

Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer

Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has

1 2

People

Cathie Wood

643 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.